Genmab has signed an agreement to buy all shares of clinical-stage biotechnology company Merus at $97 per share, in an all-cash transaction valued at $8bn, boosting its oncology pipeline. The acquisition, which has received unanimous support from both companies' boards of directors, is expected to advance Genmab's transition to a fully owned business model. A subsidiary of Genmab will initiate a tender offer to acquire 100% of the common shares of Merus, with the deal projected to close early in the firs ...

此次要约收购中支付的每股普通股 97.00 美元的收购价格较 Merus 2025 年 9 月 26 日的收盘价 68.89 美 元溢价约 41%，较 Merus 30 天成交量加权平均价 67.42 美元溢价约 44%。 来源：市场资讯 （来源：求实药社） 当地时间 9 月 29 日，Genmab A/S 和 Merus NV 今日宣布，双方已达成交易协议。根据协议，Genmab 拟以每股 97.00 美元的价格全现金收购 Merus 的全部股份。此次收购将以现金方式进行，交易价值约为 80 亿美元。 该交易已获得两家公司董事会的一致批准。Genmab 的全资子公司将对 Merus 100% 的普通股发起要约 收购，预计将于 2026 年第一季度初完成。 | 0 = 00 | CARD STORE FOR CONSULTION CONSULTION CONSULTION OF CONSULTION OF | | --- | --- | | [ Global M Genmab | Nealthcare Professionals Patterco & Care Partnerships Contact AND ...

点击蓝字，关注我们 今日上午港股 1. 中国中冶(01618)涨近7%， 机构称矿产资源丰富的建筑企业价值亟待重估。 2. 荣昌生物(09995)再涨超5%， 眼科创新药RC28申报上市，此前已与参天中国达成合作。 3. 来凯医药-B(02105)再涨近6%， 近三个交易日累计涨36%，LAE102 I期临床MAD研究初步结果积极。 4. 优必选(09880)涨超5%， 招商证券国际发表报告指，人形机器人链整机首推优必选，该行上调优必选 目标价。 9. 五矿资源(01208)涨超2%， 拟发行5亿美元于2030年到期的零息可换股债券，用于境外债务再融资。 10. 中国中车(01766)涨超1%， 9月29日，中国中车发布公告，公司及下属企业近三个月合计签订约543.4 亿重大合同。 昨日 美股 1. 阿里巴巴(BABA.US)涨4.65%， 摩根士丹利发表布研报，重申对阿里巴巴"增持"评级，ADR目标价由1 65美元上调至200美元。 2. 理想汽车(LI.US)涨3.57%， 9月27日，理想i6正式于常州智能制造基地开启交付。里昂发研报指，i6车 款销售表现料优于i8。 3. 京东(JD.US)涨0.15 ...

收购交易概述 - 公司以每股97美元现金收购Merus N V 交易总额约80亿美元[1][6] - 交易预计于2026年第一季度初完成 将显著增强公司肿瘤治疗产品组合[1][3] 战略价值与业务影响 - 获得Merus三期临床阶段资产petosemtamab 加速公司向全所有权模式转型[3][6] - 收购后公司将拥有四个专有项目 推动多款新药上市并多元化收入来源[4] - 交易支持公司持续增长至未来十年 强化其在制药行业地位[3][4] 市场反应与股价表现 - Merus股价在公告后上涨38% 显示市场对交易持积极态度[5] - Leerink Partners给予公司34美元目标价 较当前29.33美元存在16.61%上行空间[2][6] - 公司股票当日交易区间28.36-29.34美元 年内波动区间17.24-29.52美元[2][5] 公司基本面 - 当前市值约185.1亿美元 纳斯达克日成交量503万股[4] - 股价近期微涨0.89% 单日变动0.26美元[2]

公司核心业务 - 专注于开发创新癌症疗法 特别是双特异性抗体技术[1] - 主要竞争对手为Genmab A/S 目前正与该公司进行重大交易[1] 股价表现与估值 - 当前股价94.12美元 过去一年大幅上涨36.62%[3] - 股价区间在过去一年介于33.19美元至94.55美元之间[4] - 公司市值约71.2亿美元 显示其在生物技术领域的重要地位[4] - 今日交易量达1486万股 显示投资者兴趣浓厚[5] 并购交易进展 - Genmab A/S同意以每股97美元价格收购公司[2] - Wells Fargo设定97美元目标价 较当前股价存在2.69%上涨空间[2] - 当前股价94.46美元 接近收购报价水平[2] 交易合规性审查 - Halper Sadeh LLC正在调查97美元收购价对股东是否公平[3] - 调查重点在于公司董事会是否尽到对股东的受托责任[3] - 利益相关方密切关注以确保收购价格反映公司真实价值[5]

I publish my best ideas and top coverage on the Growth Stock Forum . If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button . And to go deeper, sign up to Growth Stock Forum.He leads the investing group Growth Stock Forum which features: a model portfolio of 15-2 ...

U.S. stocks were mixed, with the Nasdaq Composite gaining more than 100 points on Monday.Shares of Tilray Brands, Inc. (NASDAQ: TLRY) rose sharply during Monday's session.Shares of cannabis-linked stocks traded higher after President Donald Trump posted a video on Truth Social on Sunday, promoting the potential health benefits of cannabis. Cannabis stocks lit up on Monday after Trump resurrected hopes for a change in federal drug policy.Tilray Brands shares jumped 39.2% to $1.5983 on Monday.Here are some ot ...

Genmab A/S (NASDAQ: GMAB) on Monday agreed to acquire Merus N.V. (NASDAQ: MRUS) with its late-stage asset petosemtamab, which is in Phase 3 development, for $97 per share in an all-cash transaction representing a transaction value of approximately $8 billion. The transaction is anticipated to close by early in the first quarter of 2026. The proposed acquisition of Merus is expected to accelerate Genmab’s shift to a wholly owned model, expanding and diversifying the company’s revenue, driving sustained gro ...

BREAKING: Futures Climb With Tesla Deliveries, September Payrolls On Tap Genmab (GMAB), on Monday, announced its plan to buy cancer-focused biotech company Merus (MRUS) for about $8 billion. The news sent Merus stock into the stratosphere. Merus is working on a drug called petosemtamab, which can simultaneously block two drivers of cancer. Its most advanced program is in head-and-neck cancer, but Merus is also testing the drug in patients with metastatic colorectal cancer. Petosemtamab could generate $3 bi ...

Last week's small market swoon is a distant memory with US equity futures up sharply on Monday, led by tech and small caps as the S&P looks to set a new ATH. As of 8:00am ET, S&P futures are up 0.5% (and off session highs) keeping the benchmark on track for its best September since at least 2013, even as the month is typically difficult for stocks. Mag7 / Semis are mostly higher premarket, and with Cyclicals leading Defensives after last week's stumble, the AI Theme looks resurgent again, helping sending Eu ...